Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)‏ by John C. Byrd, Amy S. Ruppert,

Slides:

Advertisements

Similar presentations

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.

Advertisements

A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion.

Monitoring By Chromosome Banding Analysis (CBA) and FISH Of Circulating CD34+ Cells In Low-Risk MDS Patients Treated In The Le-Mon-5 Study With Lenalidomide.

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.

Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection by Koen Van Besien, Sonali Smith,

The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve.

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study by Neil P. Shah, François.

Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)‏ by Paolo Strati, Michael J. Keating,

Stage C or not stage C…? by Claire Dearden Blood

Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial by Peter Dreger,

Patients’ priorities in selecting chronic lymphocytic leukemia treatments by Carol Mansfield, Anthony Masaquel, Jessie Sutphin, Elisa Weiss, Meghan Gutierrez,

by Michael F. Leahy, and J. Harvey Turner

How I treat refractory CLL

Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL by Christian H. Geisler, Mars.

Anergy: the CLL cell limbo

Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232 by Michael J. Borowitz,

by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T

Development and Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and Identify B-Precursor Acute Lymphoblastic.

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p by James I. Barnes, Vasu Divi,

Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma by Young Ae Kim, Ja Min Byun, Keeho Park, Gi Hwan Bae, Dukhyoung.

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB (Alliance)‏ by Gail J. Roboz, Sumithra J. Mandrekar,

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

by Kaiwen Chen, Matthew P. Cheng, Sarah P

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission by Sumithira Vasu, Jessica.

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL by Farhad Ravandi, Megan.

Volume 2(Supplement 1):1-3

Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib by Cecelia R. Miller, Amy S. Ruppert,

Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib by Tracy E. Wiczer, Lauren B. Levine, Jessica.

Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

Plasma biomarker concentrations between study groups.

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM by Sundar Jagannath, Rafat Abonour,

by Christine L. Kempton, and Amanda B. Payne

Volume 2(Supplement 1):46-49

by Michael R. DeBaun, and Ellen Wright Clayton

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma by Nidhi Tandon, Surbhi Sidana, S. Vincent Rajkumar,

Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis by Samuel Yamshon,

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry by Donald M. Arnold, Ishac Nazy, Rumi.

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia by Benjamin L. Lampson, Haesook T. Kim, Matthew.

Prognostic value of D-dimer and markers of coagulation for stratification of abdominal aortic aneurysm growth by Alexandra C. Sundermann, Keith Saum, Kelsey.

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL by Anthony R. Mato, Lindsey E. Roeker,

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.

Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study by Jeffrey.

Impact of age on clinical risk scores in follicular lymphoma

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.

Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations by Ami B. Patel, Erin M. Pettijohn,

Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) in Elderly Patients with Comorbidities: Analysis of the CLL11.

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML by Jeffrey.

The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia by Amy K. Keating, Jurgen Langenhorst, John.

A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.

Initial treatment of CLL: integrating biology and functional status

by Todd A. Fehniger, Sarah Larson, Kathryn Trinkaus, Marilyn J

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.

Cold agglutinin disease

Presentation transcript:

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)‏ by John C. Byrd, Amy S. Ruppert, Nyla A. Heerema, Alese E. Halvorson, Eva Hoke, Mitchell R. Smith, John E. Godwin, Stephen Couban, Todd A. Fehniger, Michael J. Thirman, Martin S. Tallman, Frederick R. Appelbaum, Richard M. Stone, Sue Robinson, Julie E. Chang, Sumithra J. Mandrekar, and Richard A. Larson BloodAdv Volume 2(14):1705-1718 July 24, 2018 © 2018 by The American Society of Hematology

John C. Byrd et al. Blood Adv 2018;2:1705-1718 © 2018 by The American Society of Hematology

CONSORT diagram. CONSORT diagram. Arm A = FR. Arm B = FR+L. Arm C = FCR. Arm D = FCR+L. John C. Byrd et al. Blood Adv 2018;2:1705-1718 © 2018 by The American Society of Hematology

PFS and OS. (A) PFS for patients with non-del(11q) disease and assigned to FR, FR+L, or FCR. (B) PFS for patients with del(11q) disease and assigned to FCR or reassigned to FCR+L. PFS and OS. (A) PFS for patients with non-del(11q) disease and assigned to FR, FR+L, or FCR. (B) PFS for patients with del(11q) disease and assigned to FCR or reassigned to FCR+L. (C) OS for patients with non-del(11q) disease and assigned FR, FR+L, or FCR. (D) OS for patients with del(11q) disease and assigned to FCR or reassigned to FCR+L. John C. Byrd et al. Blood Adv 2018;2:1705-1718 © 2018 by The American Society of Hematology